iRadimed (NASDAQ:IRMD) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

iRadimed Corporation (NASDAQ:IRMD) shares crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $94.77 and traded as low as $85.57. iRadimed shares last traded at $88.02, with a volume of 106,372 shares trading hands.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Weiss Ratings cut shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, August 3rd. Wall Street Zen cut iRadimed from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $120.00.

iRadimed Price Performance

The stock has a market cap of $1.12 billion, a price-to-earnings ratio of 48.89 and a beta of 0.90. The stock’s 50 day simple moving average is $93.87 and its two-hundred day simple moving average is $94.70.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. The company had revenue of $20.47 million during the quarter, compared to analysts’ expectations of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, analysts predict that iRadimed Corporation will post 1.98 earnings per share for the current year.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Shareholders of record on Friday, August 14th will be paid a dividend of $0.20 per share. The ex-dividend date is Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is currently 44.69%.

Insiders Place Their Bets

In other news, CEO Roger E. Susi sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.60, for a total value of $226,500.00. Following the sale, the chief executive officer directly owned 2,162,500 shares in the company, valued at approximately $195,922,500. This represents a 0.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 34.60% of the company’s stock.

Institutional Trading of iRadimed

Large investors have recently bought and sold shares of the stock. Baader Bank Aktiengesellschaft acquired a new stake in shares of iRadimed in the fourth quarter valued at $595,000. Bridge City Capital LLC lifted its position in iRadimed by 19.4% during the 4th quarter. Bridge City Capital LLC now owns 70,854 shares of the medical equipment provider’s stock worth $6,893,000 after buying an additional 11,509 shares in the last quarter. RFG Advisory LLC bought a new stake in iRadimed during the 4th quarter worth about $1,594,000. Arrowstreet Capital Limited Partnership increased its position in iRadimed by 144.8% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 15,445 shares of the medical equipment provider’s stock valued at $1,487,000 after acquiring an additional 9,136 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of iRadimed by 4.2% in the first quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock worth $21,768,000 after acquiring an additional 9,017 shares during the last quarter. 92.34% of the stock is currently owned by institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.